bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2018: J J M A M F J
2017: D N O S A J

 
  Other news for:
Hematologic Diseases
Hemophilia A
 Resources from HONselect
New Hemophilia Treatment Stems Bleeding Episodes

By Scott Roberts

THURSDAY, Nov. 16, 2017 (HealthDay News) -- Hemlibra (emicizumab-kxwh) has been approved by the U.S. Food and Drug Administration to prevent or reduce the number of bleeding episodes among certain people with hemophilia A.

The injected drug was approved for patients with antibodies called Factor VIII inhibitors. People with hemophilia A are missing a gene that produces Factor VIII, a blood-clotting protein.

Hemophilia affects about one of 5,000 babies born in the United States, some 80 percent of whom have Hemophilia A, the FDA said Thursday in a news release. Most babies born with the genetic disease are male.

Hemophilia A can trigger episodes of bleeding into the joints, leading to severe damage. Some people with the disease develop antibodies that interfere with standard treatments.

"Today's approval provides a new preventive treatment that has been shown to significantly reduce the number of bleeding episodes in patients with hemophilia A with Factor VIII inhibitors," said Dr. Richard Pazdur, acting director of the agency's Office of Hematology and Oncology Products. "In addition, patients treated with Hemlibra reported an improvement in their physical functioning."

Common side effects of the drug, given preventively every week, include injection site reaction, headache and joint pain.

The drug's label includes a boxed warning of possible blood clots among recipients who also are given anti-bleeding medication, the FDA said.

Hemlibra is produced by Genentech, based in South San Francisco.

Learn more from the FDA.

SOURCE: Nov. 16, 2017 press release, U.S. Food and Drug Administration

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=728600

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Hemorrhage
Therapeutics
Factor VIII
Joints
Affect
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact